Philip T. Cagle • Timothy Craig Allen
Mary Beth Beasley • Lucian R. Chirieac
Sanja Dacic • Alain C. Borczuk
Keith M. Kerr
Editors

2012

The past few years have seen a revolution in the molecular pathology of lung cancer, including exciting advances in predictive biomarker testing and molecular targeted therapy. Clinical trials in 2009 demonstrated the superiority of tyrosine kinase inhibitor therapy to conventional chemotherapy in patients with advanced lung cancers with activating epidermal growth factor receptor (EGFR) mutations.